Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

61.49USD
18 Aug 2017
Change (% chg)

$-0.32 (-0.52%)
Prev Close
$61.81
Open
$61.74
Day's High
$61.81
Day's Low
$61.17
Volume
3,622,812
Avg. Vol
2,857,832
52-wk High
$66.80
52-wk Low
$58.29

Latest Key Developments (Source: Significant Developments)

Merck & Co says received investigative subpoena from california insurance commissioner’s fraud liaison bureau - sec filing
Tuesday, 8 Aug 2017 05:28pm EDT 

Aug 8 (Reuters) - Merck & Co Inc :Merck & co says recently received investigative subpoena from california insurance commissioner’s fraud liaison bureau - sec filing.Merck - the fraud liaison bureau investigating if cubist pharmaceuticals unlawfully induced presentation of false claims for cubicin to private insurers.Merck & co - investigative subpoena from fraud liaison bureau seeks information from jan 1, 2007 to present related to pricing and promotion of cubicin‍​.  Full Article

Sanofi files suit in U.S. to defend patent rights on Lantus
Tuesday, 8 Aug 2017 03:32pm EDT 

Aug 8 (Reuters) - Sanofi SA ::Sanofi files suit in the U.S. to defend its patent rights on Lantus.Says ‍filed a patent infringement suit against Merck Sharp & Dohme Corp​.Says ‍in its suit co alleges infringement of two patents​.  Full Article

MSD Animal Health to purchase manufacturing facility in Krems, Austria
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Merck & Co Inc :MSD Animal Health to purchase manufacturing facility in Krems, Austria.Merck & Co Inc - ‍additional terms of deal will not be disclosed.​.Merck & Co Inc - ‍MSD Animal Health intends to immediately begin renovating facility and expects to be ready for production in coming years​.Merck & Co Inc - facility, currently owned by Shire PLC., was built in 2002 and will add to company's global manufacturing capabilities.  Full Article

Generex announces collaboration with Merck to evaluate Keytruda in combination with ae37 in patients with triple-negative breast cancer
Monday, 31 Jul 2017 09:30am EDT 

July 31 (Reuters) - Generex Biotechnology Corp :Generex announces collaboration with Merck to evaluate keytruda (pembrolizumab) in combination with ae37 in patients with triple-negative breast cancer.Generex Biotechnology Corp - ‍antigen express has entered into a clinical trial collaboration agreement with merck​.Generex Biotechnology Corp - ‍additional details were not disclosed​.Generex Biotechnology Corp - under terms of agreement, trial will be sponsored by antigen express.  Full Article

Merck reports Q2 non-GAAP earnings of $1.01/shr
Friday, 28 Jul 2017 06:45am EDT 

July 28 (Reuters) - Merck & Co Inc :Merck announces second-quarter 2017 financial results.Q2 non-GAAP earnings per share $1.01.Q2 GAAP earnings per share $0.71.Q2 sales $9.9 billion versus I/B/E/S view $9.75 billion.Q2 earnings per share view $0.87 -- Thomson Reuters I/B/E/S.Merck & Co Inc qtrly Keytruda sales $‍881​ million versus $314 million.Merck & Co Inc - Q2 Januvia/Janumet sales $‍1,511​ million versus $1,634 million.Merck & Co Inc- Q2 Remicade sales $ 208 million versus $339 million.Merck & Co Inc - ‍company reduces 2017 full-year GAAP EPS range to be between $1.60 and $1.72.Merck & Co Inc - ‍second-quarter pharmaceutical sales increased 1 percent to $8.8 billion, including a 1 percent negative impact from foreign exchange​​.Sees FY 2017 non-GAAP earnings per share $3.76 to $3.88 including items.Merck & Co Inc - ‍continues to expect 2017 full-year non-GAAP EPS range to be between $3.76 and $3.88​.FY 2017 earnings per share view $3.85 -- Thomson Reuters I/B/E/S.Merck & Co - Narrows and raises 2017 FY revenue range to be $39.4 billion - $40.4 billion, including approximately 1 percent negative impact from foreign exchange​.FY 2017 revenue view $40.07 billion -- Thomson Reuters I/B/E/S.Merck & Co Inc - sees FY restructuring costs of $600 million.Merck & Co Inc - sees FY acquisition- and divestiture-related costs of $3,600 million.Merck & Co Inc - ‍anticipates that it will have temporary delays in fulfilling orders for certain products in certain markets​.  Full Article

Astrazeneca says establish strategic oncology collaboration with Merck
Thursday, 27 Jul 2017 02:06am EDT 

July 27 (Reuters) - Astrazeneca Plc ::ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION.ASTRAZENECA PLC - ASTRAZENECA AND MERCK WILL INDEPENDENTLY DEVELOP AND COMMERCIALISE LYNPARZA AND POTENTIAL MEDICINE SELUMETINIB IN COMBINATIONS WITH COMPANIES' RESPECTIVE.MERCK WILL PAY CO UP TO $8.5 BILLION IN TOTAL CONSIDERATION.ASTRAZENECA- COS TO SHARE DEVELOPMENT, COMMERCIALISATION COSTS FOR LYNPARZA, SELUMETINIB MONOTHERAPY, NON-PD-L1/PD-1 COMBINATION THERAPY OPPORTUNITIES.ASTRAZENECA PLC - MERCK WILL FUND ALL DEVELOPMENT AND COMMERCIALISATION COSTS OF KEYTRUDA IN COMBINATION WITH LYNPARZA OR SELUMETINIB.ASTRAZENECA PLC - ASTRAZENECA WILL FUND ALL DEVELOPMENT AND COMMERCIALISATION COSTS OF IMFINZI IN COMBINATION WITH LYNPARZA OR SELUMETINIB.ASTRAZENECA PLC - ASTRAZENECA WILL CONTINUE TO MANUFACTURE LYNPARZA AND SELUMETINIB.UNDER TERMS OF AGREEMENT, ASTRAZENECA ANTICIPATES APPROXIMATELY $1 BILLION TO BE RECORDED UNDER EXTERNALISATION REVENUE IN 2017.COLLABORATION AGREEMENT WAS COMPLETED UPON SIGNING ON 26 JULY 2017.ASTRAZENECA PLC - MERCK WILL PAY ASTRAZENECA UP TO $8.5 BILLION IN TOTAL CONSIDERATION.  Full Article

Merck sets quarterly dividend of $0.47 per share
Tuesday, 25 Jul 2017 03:57pm EDT 

July 25 (Reuters) - Merck and Co Inc :Sets quarterly dividend of $0.47 per share.  Full Article

Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint
Tuesday, 25 Jul 2017 08:35am EDT 

July 25 (Reuters) - Merck & Co Inc ::Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint of non-inferiority to efavirenz, both in combination with other antiretroviral agents, in pivotal phase 3 trial for treatment of hiv-1 infection.Merck & Co Inc - ‍merck plans to submit new drug applications with U.S. FDA in Q4 2017​.Merck & Co Inc - Merck plans to submit new drug applications with U.S. FDA in Q4 2017.Merck & Co Inc - ‍treatment discontinuations due to adverse events for dor/3tc/tdf and efv/ftc/tdf were 3 percent and 7 percent, respectively​.  Full Article

Merck provides update on phase 3 study of keytruda
Monday, 24 Jul 2017 05:00pm EDT 

July 24 (Reuters) - Merck & Co Inc ::Merck provides update on phase 3 study of keytruda® (pembrolizumab) monotherapy in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma (hnscc).Merck & Co Inc - ‍no new safety signals were identified in study​.Says ‍"we remain confident that keytruda is an important therapy for this difficult-to-treat cancer"​.Merck & Co Inc - ‍safety profile observed in keynote-040 was consistent with that observed in previously reported studies of keytruda​.Merck & Co Inc - anti-pd-1 therapy, did not meet its pre-specified primary endpoint of overall survival.  Full Article

Merck announces week 96 results from Oncemrk
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Merck & Co Inc :Merck announces week 96 results from Oncemrk, a study evaluating once-daily Isentress HD (raltegravir), in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients.Once-daily version of raltegravir now approved in U.S. and European Union.Week 96 results reaffirm comparable efficacy and safety of Isentress HD.  Full Article

Photo

FDA expands use of AstraZeneca/Merck ovarian cancer drug

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.